Key Takeaways BD received FDA 510(k) clearance for its EnCor EnCompass Breast Biopsy and Tissue Removal System.BDX plans an early 2026 launch, offering a multi-modality platform to improve flexibility and workflow.The system supports early detection with precision features designed to enhance confidence.Becton, Dickinson and Company(BDX) , popularly known as BD, recently announced that the FDA has granted 510(k) clearance for its EnCor EnCompass Breast Biopsy and Tissue Removal System. Anticipated to launch ...